New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
18:05 EDTZTSZoetis could climb 25%, Barron's says
Zoetis (ZTS) isn't subject to the same patent expiration cliff as Pfizer (PFE) and earnings should rise 13% over the next few years, Barron's says in its "Weekday Trader" column. Shares could climb 25%, the paper adds. Reference Link
News For ZTS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 3, 2015
16:32 EDTZTSZoetis receives conditional license from USDA
Zoetis announced that the U.S. Department of Agriculture has granted the company a conditional license for Canine Atopic Dermatitis Immunotherapeutic, an antibody therapy to help reduce clinical signs associated with atopic dermatitis in dogs. The USDA has communicated that all biological products for canine atopic dermatitis will be considered for conditional licensure only at this time. Zoetis said it is working with the USDA to obtain full licensure.
July 21, 2015
16:25 EDTZTSZoetis files automatic mixed securities shelf
Subscribe for More Information
06:58 EDTZTSZoetis added to US 1 List at BofA/Merrill

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use